Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
TARE vs SBRT for HCC (talk): both deliver ablative RT, phenotype picks the modality; SBRT favored with MVI, arterial constraints, or non-invasive preference. No effect size reported in source.
Hepatobiliary only today, a decision-framework talk, not a readout. SBRT is independent of lung shunt and arterial anatomy and needs no arterial access or sedation; TARE is often advantageous when tumor abuts luminal GI structures. BEACON-HCC (Hepatology 2026) lists both as 1st line options. No LC, OS, or toxicity data on the shared slides.
read the full digest →Studies · 150
- TARE vs SBRT for HCC: decision-making talkBoth TARE and SBRT can deliver ablative RT in HCC; phenotype should pick the modality, SBRT attractive with MVI, arterial constraints, or non-invasive preference.
- NRG/RTOG 0815 Decipher GC score and STAD benefitAdding STAD to RT cut 10-yr DM by 8% absolute in Int/High GC vs 1% in Low GC, intermediate-risk prostate (n=395).
- GETUG P055-yr bPFS 88% vs 88.2% (p=0.90) for brachy boost vs 80 Gy EBRT in intermediate-risk PCa without ADT; late GU toxicity higher with boost.
- LUNAR vs SATURNMedian time to progression 19.4 mo with SBRT + 177Lu-PNT2002 vs 21.7 mo with SBRT + 6 mo AAT; IPTW-adjusted HR 1.39 (0.56-3.45), p=0.47.
- NRG/RTOG 0534 SPPORT PAM50 subtypesPAM50 Luminal B predicted STADT benefit with salvage RT: 5-y FFP gain 31% vs 10% non-Luminal B (p-int=.01); 10-y MFS 20% vs -3%.
- NRG/RTOG 0815 long-term follow-upOS HR 0.87, p=0.13 (not met), but 6 mo STAD cut PSA failure (HR 0.60) and DM (HR 0.35) in intermediate-risk PCa on dose-escalated RT.
- PROSTOX Ultra post-prostatectomy SBRT (SCIMITAR, EXCALIBUR)Germline 32-mirSNP score kept continuous AUC 0.814/0.824 for late G2+ GU AEs after post-op SBRT; intact 0.50 cutoff failed, recalibrated 0.25 gave pooled AUC 0.748.
- Post-operative biomarkers in prostate cancer (Spratt, ASTRO 2026)PAM50 luminal B selected apalutamide benefit with salvage RT in NRG GU006 (5yr MFS 95% vs 82%, HR 0.27); non-luminal B showed none.
- GUAM international consensus guideline on GU adverse events after prostate RTDelphi panel (48 experts, ≥75% agreement): 76% favor moderate hypofx over SBRT at baseline IPSS 15–19; no dose-volume constraint reached consensus.
- REVELUTION (relugolix vs leuprolide + RT, PROs)At 12 mo, relugolix vs leuprolide with RT: IPSS 5.66 vs 9.22 (p=0.039), EPIC-CP total 12.25 vs 17.25 (p=0.02); post hoc.
- RTOG 3506 (STEEL)PFS HR 0.62 (80% CI 0.42-0.91, one-sided p=0.052) adding enzalutamide to SRT + 24mo ADT in high-risk post-RP BCR; BF at 2y 11% vs 19%.
- SWOG S1827/MAVERICKMRI surveillance alone beat MRI + PCI for cognitive failure-free survival, HR 0.60 (90% CI 0.46-0.78), in LS- and ES-SCLC without brain mets after first-line therapy.